Summary
Faster run times for GLP-1, insulin, and LNP drug substance testing accelerates biopharmaceutical development timelines and reduces production bottlenecks. Delivers up to 2x increase in resolving power and sensitivity to identify and track low-level impurities for improved regulatory…
Source: Pr Newswire
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
